Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response-adapted maintenance versus standard rituximab maintenance in advanced follicular lymphoma
2012-003170-60Phase 3Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, ibritumomab tiuxetan, cyclophosphamide, doxorubicin, vincristine in follicular lymphoma (FL), sponsored by Fondazione Italiana Linfomi. Started Aug 2012; status: completed.
02
Drugs
rituximabibritumomab tiuxetancyclophosphamidedoxorubicinvincristine
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2012-003170-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003170-60.